| Value | ₹2,500 Cr |
|---|
BSE filing, NSE: POONAWALLA. Summary written from the filing by ALFA Finder's alert engine.
Poonawalla Fincorp Ltd: key numbers
- Share price
- ₹461.70
- Market cap
- ₹40,657 Cr
- Revenue (annual)
- ₹6,790 Cr
- Net profit (annual)
- ₹541.8 Cr
- P/E (TTM)
- 37.4×Sector 19.8×
- Promoter holding
- 59.01%-0.01% QoQ
- FII holding
- 11.64%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Poonawalla Fincorp Ltd
All →Poonawalla Fincorp Debt & Borrowing: ₹12.35 Cr
Poonawalla Fincorp paid Rs.12.35 Crore interest on its Rs.500 Crore NCDs (ISIN INE511C07AB9) on time, 30 October 2026. The payment was made under Regulation 57 with no delay.
- Value
- ₹12.35 Cr
Poonawalla Fincorp Debt & Borrowing: ₹1,318 Cr
Poonawalla Fincorp allotted Rs 1,318 Crore NCDs across two series G1 and G2. The allotment comprises zero-coupon and 9% coupon debentures maturing by 2030.
- Value
- ₹1,318 Cr
Poonawalla Fincorp Debt & Borrowing: ₹2,000 Cr
Poonawalla Fincorp approved ₹2,000 Crore secured NCD issuance via private placement in two series. Debentures carry first-ranking pari passu charge and will be listed on BSE.
- Value
- ₹2,000 Cr
Poonawalla Fincorp Annual General Meeting
Poonawalla Fincorp Ltd issued a postal ballot notice seeking shareholder approval for the re-appointment of Ms. Kemisha Soni as an Independent Director for a second term.
Poonawalla Fincorp Debt & Borrowing
Poonawalla Fincorp confirmed the timely redemption of Commercial Paper maturing on October 16, 2026. This filing fulfills regulatory reporting requirements for debt obligations.
Poonawalla Fincorp Management Change
Poonawalla Fincorp Limited has re-appointed Ms. Kemisha Soni as a Non-Executive Independent Director for a 36-month term, effective October 9, 2026.
Other fund raise announcements
All →Sudarshan Pharma Industries Fund Raise of ₹72 Cr
Sudarshan Pharma's board approved up to Rs. 72 Crore of preferential convertible warrants for promoters Hemal and Sachin Mehta. Shareholder approval will be sought at an EGM.
- Value
- ₹72.00 Cr
Flywings Simulator Training Centre Fund Raise of ₹68.2 Cr
Flywings Simulator's board approved Rs. 68.20 Crore fully convertible warrants on a preferential basis. Promoter Rupal Mandavia is allotted Rs. 25 Crore, subject to shareholder approval.
- Value
- ₹68.20 Cr
Kanel Industries Fund Raise of ₹16.99 Cr
Kanel Industries' board approved a rights issue of 42.52 lakh equity shares at Rs.39.95 each. The issue aggregates about Rs.16.99 Crore, with record date 13 November 2026.
- Value
- ₹16.99 Cr
- Execution
- Rights issue opens 23 November 2026 and closes 30 November 2026
Sudarshan Pharma Industries Fund Raise
Board approved issuing up to 72 Crore warrants to promoters on a preferential basis. Pricing per Reg 164 is pending, with no fixed rupee value stated.
GAIL (India) Fund Raise
GAIL Board approved in principle the IPO of subsidiary GAIL Gas Limited on Indian exchanges. GAIL will dilute its GGL equity up to 25%.
Gujarat Inject (Kerala) Fund Raise of ₹3 Cr
Gujarat Inject Kerala's board approved a Rs.3 Crore preferential warrant issue to public investors. Authorised capital will rise to Rs.17.63 Crore, subject to shareholder approval.
- Value
- ₹3.00 Cr